Compare MGY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGY | ACAD |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.4B |
| IPO Year | 2017 | 2000 |
| Metric | MGY | ACAD |
|---|---|---|
| Price | $23.93 | $18.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | ★ $32.82 | $30.53 |
| AVG Volume (30 Days) | ★ 2.7M | 2.5M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | 0.24 | ★ 0.51 |
| Revenue | ★ $1,311,845,000.00 | $726,437,000.00 |
| Revenue This Year | $58.77 | $19.43 |
| Revenue Next Year | $34.33 | $13.21 |
| P/E Ratio | $98.71 | ★ $36.08 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $21.07 | $15.86 |
| 52 Week High | $32.76 | $30.96 |
| Indicator | MGY | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 38.95 |
| Support Level | $23.40 | N/A |
| Resistance Level | $27.79 | $22.71 |
| Average True Range (ATR) | 0.81 | 1.10 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 39.96 | 34.91 |
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area of South Texas, where it targets the Eagle Ford Shale and Austin Chalk formations. It focuses on generating value for shareholders by delivering steady, moderate annual production growth resulting from its capital spending philosophy. The company operates in only one segment and derives the majority of its revenue from the sale of crude oil, natural gas, and natural gas liquids (NGLs).
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.